Published
## Filings that contain financial statements - **Form 8-K, accession 0000014272-26-000018 (filed July 30, 2026)** — Exhibit 99.1 furnishes Bristol Myers Squibb's second-quarter 2026 earnings release, including the GAAP and non-GAAP income-statement summary, product-revenue tables and cost/expense detail for the three months ended June 30, 2026 (with June 30, 2025 comparatives). - **Form 8-K, accession 0000014272-26-000008 (filed April 30, 2026)** — Exhibit 99.1 furnishes the first-quarter 2026 earnings release, with the same income-statement, product-revenue and cost/expense detail for the three months ended March 31, 2026 (with March 31, 2025 comparatives). - **Form 8-K, accession 0000014272-26-000002 (filed February 5, 2026)** — Exhibit 99.1 furnishes the fourth-quarter and full-year 2025 earnings release, including GAAP and non-GAAP income statement detail for both the quarter and full year ended December 31, 2025 (with 2024 comparatives). - **Form 8-K, accession 0000014272-25-000147 (filed October 30, 2025)** — Exhibit 99.1 furnishes the third-quarter 2025 earnings release, with income-statement, product-revenue and cost/expense detail for the three months ended September 30, 2025. - **Form 8-K, accession 0000014272-25-000129 (filed July 31, 2025)** — Exhibit 99.1 furnishes the second-quarter 2025 earnings release for the three months ended June 30, 2025. - **Form 8-K, accession 0000014272-25-000089 (filed April 24, 2025)** — Exhibit 99.1 furnishes the first-quarter 2025 earnings release for the three months ended March 31, 2025. - **Form 8-K, accession 0000014272-25-000037 (filed February 6, 2025)** — Exhibit 99.1 furnishes the fourth-quarter and full-year 2024 earnings release. ## Earnings and guidance - **July 30, 2026 (accession 0000014272-26-000018):** Second-quarter 2026 revenue rose 6% (5% ex-FX) to $13.0 billion, with Growth Portfolio revenue up 15% to $7.6 billion. GAAP EPS was $1.62 and non-GAAP EPS was $2.04. The company raised full-year 2026 revenue guidance to approximately $49.0–$50.0 billion (from $46.0–$47.5 billion) and raised non-GAAP EPS guidance to $6.75–$7.00 (from $6.05–$6.35), citing broad-based portfolio momentum. - **April 30, 2026 (accession 0000014272-26-000008):** First-quarter 2026 revenue rose 3% (1% ex-FX) to $11.5 billion, with Growth Portfolio revenue up 12% to $6.2 billion. GAAP EPS was $1.31 and non-GAAP EPS was $1.58. The company reaffirmed its 2026 guidance of ~$46.0–$47.5 billion in revenue and $6.05–$6.35 non-GAAP EPS, noting results were trending toward the upper end of both ranges. - **February 5, 2026 (accession 0000014272-26-000002):** Fourth-quarter 2025 revenue rose 1% to $12.5 billion; full-year 2025 revenue was $48.2 billion, essentially flat year over year. Full-year GAAP EPS was $3.46 (versus a GAAP loss of $4.41 per share in 2024) and non-GAAP EPS was $6.15. The company issued initial 2026 guidance of ~$46.0–$47.5 billion in revenue and $6.05–$6.35 non-GAAP EPS, and raised the quarterly common dividend to $0.63 per share — the 17th consecutive annual increase. - **October 30, 2025 (accession 0000014272-25-000147):** Third-quarter 2025 revenue rose 3% (2% ex-FX) to $12.2 billion, with Growth Portfolio revenue up 18% to $6.9 billion. GAAP EPS was $1.08 and non-GAAP EPS was $1.63. The company raised full-year 2025 revenue guidance to ~$47.5–$48.0 billion (from ~$46.5–$47.5 billion) and updated non-GAAP EPS guidance to $6.40–$6.60. - **July 31, 2025 (accession 0000014272-25-000129):** Second-quarter 2025 revenue was $12.3 billion, with Growth Portfolio revenue up 18% to $6.6 billion. GAAP EPS was $0.64 and non-GAAP EPS was $1.46, both including a $(0.57) per-share impact from an Acquired IPRD charge tied to the BioNTech collaboration. The company raised full-year 2025 revenue guidance to approximately $46.5–$47.5 billion, updated non-GAAP EPS guidance to $6.35–$6.65 (inclusive of the $(0.57) BioNTech impact), and now expected full-year operating expenses of approximately $16.5 billion. - **April 24, 2025 (accession 0000014272-25-000089):** First-quarter 2025 total revenues were $11,201 million, down 6% (down 4% ex-FX). GAAP EPS was $1.20 and non-GAAP EPS was $1.80 for the quarter, as later referenced in the first-quarter 2026 release's comparative figures. - **February 6, 2025 (accession 0000014272-25-000037):** Fourth-quarter and full-year 2024 results were reported. ## Business development / M&A - **May 13, 2025 (Form 10-Q, accession 0000014272-26-000020, Note 4; also Form 10-K, accession 0000014272-26-000004):** Bristol Myers Squibb completed the acquisition of 2seventy bio, acquiring all outstanding shares for $5.00 per share in cash, for total consideration of $287 million, or $114 million net of cash acquired. The transaction gave BMS full U.S. rights to Abecma, a cell therapy for relapsed or refractory multiple myeloma, and was accounted for as an asset acquisition. - **June 2025 (reported in the July 31, 2025 second-quarter release, accession 0000014272-25-000129, and in Form 10-Q accession 0000014272-26-000020, Note 3):** Bristol Myers Squibb and BioNTech entered a global strategic collaboration for the co-development and co-commercialization of pumitamig (BNT327/BMS-986545), a PD-L1 x VEGF-A bispecific antibody, with the companies sharing equally in global profits and losses. BMS paid BioNTech a $1.5 billion upfront fee, recorded as an Acquired IPRD charge, during the third quarter of 2025, and will pay $2.0 billion in aggregate anniversary payments beginning in the third quarter of 2026 through 2028 absent earlier termination by BMS, plus up to $7.6 billion of contingent development, regulatory and sales-based milestones. - **October 30, 2025 (accession 0000014272-25-000147), completed December 2025 (Form 10-K, accession 0000014272-26-000004, Note 4):** Bristol Myers Squibb announced a definitive agreement to acquire Orbital Therapeutics, whose lead asset (OTX-201) is a preclinical in vivo CAR T-cell therapy candidate for autoimmune disease, subject to customary closing conditions. In December 2025, BMS completed the acquisition in an all-cash transaction for total consideration of $1.7 billion, or $1.5 billion net of cash acquired, accounted for as an asset acquisition. - **May 2026 (reported in the second-quarter 2026 release, accession 0000014272-26-000018):** Bristol Myers Squibb entered a strategic agreement with Anthropic to deploy Claude across research, clinical, manufacturing, commercial and corporate functions. - **May 2026, closed July 2026 (Form 10-Q, accession 0000014272-26-000020, Note 4):** Bristol Myers Squibb and Hengrui Pharmaceuticals entered global strategic collaboration and license agreements covering 13 early-stage oncology, hematology and immunology programs, with BMS holding exclusive worldwide rights outside mainland China, Hong Kong and Macau and Hengrui retaining exclusive rights within that territory. The transaction closed in July 2026. BMS will pay Hengrui a $600 million upfront fee in the third quarter of 2026 and a $175 million anniversary payment in 2027; Hengrui is also eligible for a second $175 million anniversary payment in 2028 absent earlier termination by BMS, up to $14.3 billion of contingent development, regulatory and sales-based milestones, and tiered royalties on net sales outside the Hengrui territory. - **July 2026 (reported in the second-quarter 2026 release, accession 0000014272-26-000018):** Bristol Myers Squibb expanded its AI collaboration with NVIDIA to deploy new AI infrastructure across research and data functions. - **Second quarter of 2026 (Form 10-Q, accession 0000014272-26-000020, Note 4):** Bristol Myers Squibb sold its 60% ownership stake in Sino-American Shanghai Squibb Pharmaceuticals Limited, recognizing net cash proceeds of $164 million and a $109 million divestiture gain. ## Capital actions (debt) - **November 3, 2025 (accession 0001140361-25-040066):** Bristol Myers Squibb commenced cash tender offers to purchase certain outstanding notes for an aggregate purchase price of up to $7 billion, split into a $4 billion "Pool 1" pool of shorter-dated notes and a $3 billion "Pool 2" pool of longer-dated notes, conditioned on completion of a new debt offering by its Irish financing subsidiary. - **November 10, 2025 (accession 0001140361-25-041380):** BMS Ireland Capital Funding Designated Activity Company, a wholly owned subsidiary, completed a €5.0 billion multi-tranche notes offering across five series maturing 2030–2055: €750 million 2.973% notes due 2030, €1,150 million 3.363% notes due 2033, €1,150 million 3.857% notes due 2038, €750 million 4.289% notes due 2045 and €1,200 million 4.581% notes due 2055, fully and unconditionally guaranteed by Bristol Myers Squibb, with proceeds net of loan issuance costs of $5.7 billion. Proceeds, together with about $3.0 billion of cash on hand, were earmarked to fund the pending tender offer. - **November 17–18, 2025 (accession 0001140361-25-042607):** The company announced early participation results and early settlement of the tender offers, amending the maximum aggregate purchase price it would accept to approximately $3.99 billion for Pool 1 (enough to accept all validly tendered Pool 1 notes) and approximately $3.51 billion for Pool 2 (enough to accept all Pool 2 notes at priority levels 1–4 plus a prorated $250 million of its 5.900% notes due 2033), with early settlement occurring November 20, 2025. Those cash amounts are purchase-price caps, not principal retired: the principal amount of notes actually accepted, cancelled and retired totaled $3,965,660,000 in Pool 1 and $3,256,627,000 in Pool 2 — about $7.2 billion of principal — for a combined cash outlay of roughly $7.5 billion. Bristol Myers Squibb's annual report for fiscal 2025 (Form 10-K, accession 0000014272-26-000004) states that, combined with related "make whole" redemptions, the company repurchased $8.7 billion in aggregate principal amount of debt in November and December 2025 for $9.1 billion of cash. ## Management changes - **July 21, 2025 (accession 0001140361-25-027350):** Dr. Samit Hirawat, Chief Medical Officer and Head of Development, announced he would leave the company by November 1, 2025, transitioning to an advisor role effective August 1, 2025. - **February 14, 2025 (accession 0001140361-25-005012):** Sandra Leung, Executive Vice President and General Counsel, notified the company of her intention to retire during 2025, remaining through a transition period. ## Other filings reviewed, not carrying material news - Annual meeting voting results on routine director elections, say-on-pay, auditor ratification and shareholder proposals (accessions 0001140361-26-020036, filed May 8, 2026, and 0001140361-25-017742, filed May 7, 2025). - An investor-presentation 8-K posted alongside a J.P. Morgan Healthcare Conference-style update (accession 0001140361-26-000929, filed January 12, 2026) contained no new financial or business information beyond prior disclosures.